Autopsy report · NCT02679131

To Evaluate Safety and Pharmacokinetics of Belinostat in Patients Who Have Mild, Moderate and Severe Renal Impairment.

Cause of deathOther Automatic label, confidence 0.3, unverified. How labels are made.

“Close out study w/o Cohort D; Severe Impairment (eGFR=15 to \<30mL/min/1.73m²)”

The sponsor’s own words in the registry.

Life of this trial

Registered 2 months before it started.
Ran for about 1 year 3 months before it stopped.
18 participants enrolled.
No results are posted on the registry.

Vital statistics

Status: Terminated
Phase: Phase 1
Sponsor: Acrotech Biopharma Inc.
Sponsor type: Industry
Conditions: Relapsed/Refractory Solid Tumors/Hematological Malignancies
Interventions: Belinostat
Participants: 18
Sites: 2
Countries: United States

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.